Review of the Early Access to Medicines Scheme (EAMS)
What the buyer wrote
The Early Access to Medicines Scheme (EAMS) aims to give patients with life threatening or seriously debilitating conditions access to medicines that do not yet have a marketing authorisation, when there is a clear unmet medical need. The scheme demonstrates a commitment from the UK to pharmaceutical innovation, providing a platform for drugs to be brought to patients at a much faster rate than ever before. We are looking for organisations that will work closely with the team to inform their wider work in developing possible solutions to the challenges of workstream 2 i.e. how the current UK landscape for development and regulation of new healthcare technologies could be streamlined and fu…
Bid for this and lost? There is a short window in which the decision can be questioned.
Awarded to
Details
- What the buyer calls it
- Review of the Early Access to Medicines Scheme (EAMS)
- How they are buying
- Advertised, open to anyoneAny supplier could bid without being invited first.
- Type
- services
- Suitable for small firms
- The buyer says yes. What that is worth
- Work starts
- 13 Sep 2015
- Work ends
- 30 Oct 2015
- Kind of work
- Research, evaluation and insight, Pharmacy and medicines
Who the buyer named
Donna Reynolds was the named contact on this notice.